By Dan Stratful
Monday 16th January 2012
|Text too small?|
Fisher & Paykel Healthcare is a quality company, but it is facing a strong NZD against most major currencies (except Australia) and it will continue to battle a high NZD in 2012.
Despite this FPH operates in a growth, defensive sector and the shares have sold off recently to reflect the strong NZD. In fact the shares have sold off so much that they are beginning to stack up from a dividend yield perspective, which at $2.20 per share provides almost an 8% gross dividend yield. Dividends are expected to remain constant in future years so the dividend yield looks sustainable.
FPH’s interim result for the six months to 30 September 2011 showed that it is still growing in constant currency terms. In US dollars, operating revenue grew 18% to US$205.7 million in the interim period which is fairly strong growth.
In the year to 31 March 2012, FPH expects continuing growth in demand for its products and is expecting constant currency growth of approximately 25% in net profit after tax for the full year ending 31 March 2012 (FY12), excluding last year’s deferred tax charges. Based on an exchange rate range of 0.75 to 0.80 for the NZD:USD for the remainder of the FY12 year, FPH expects operating revenue to be in the range of NZ$520 million to NZ$530 million and net profit after tax to be in the range of NZ$62 million to NZ$67million.
Status: Growth/Yield buy
FPH shares today traded at $2.20
For sharemarket and fixed income trading enquires contact:
Dan Stratful at Investment Research Group (IRG)
Authorised Financial Adviser (AFA)
0800 437 8489, 09 304 0232, email@example.com
**A disclosure statement is available, on request and free of charge.
In accordance with the Financial Advisers Act 2008 (“the Act”) Sharechat is “Class Advice” and any advice or recommendations contained on this webpage is not “Personalised Advice” as defined by the Act. This means Sharechat does not take into account an investor’s particular financial position, financial needs, financial goals, risk profile or asset allocation. Investor’s who require “Personalised Advice” should contact an Authorised Financial Adviser (AFA).
DISCLAIMER: To the extent that any of the content above constitutes advice, it is general advice that has been prepared without reference to investor’s objectives, financial situation or needs. Before acting on any advice, investors should consider the appropriateness of the advice and IRG recommend that investors should obtain appropriate financial, legal and taxation advice before making any financial investment decision. The report is based on information compiled from public information and private research. IRG have completed the report on a best endeavours basis and do not accept any liability of loss or damage. IRG suggest that clients use this as part of a decision making process and check key data before making any investment decisions.
Employees may have an interest in the securities discussed in this report.
No comments yet
NZ dollar rally may limit profit gains for Fisher and Paykel Healthcare, brokerage says
FISHER & PAYKEL HEALTHCARE ANNOUNCES NEW NASAL PILLOWS MASK AT INVESTOR DAY
Shares in Fisher and Paykel Healthcare third-best performer on NZX 50 after raising earnings forecast
Fisher and Paykel Healthcare raises 2014 earnings forecast on higher sales, margins
F and P Healthcare shares jump to highest in more than 2 years on profit outlook
F and P Healthcare beats 2013 guidance, forecasts boost in 2014 profit; shares gain to 2 1/2 year high
F and P Healthcare shares rise to two-year high as First NZ raises rating on better outlook
Fisher & Paykel Healthcare
F and P Healthcare lifts guidance as sales grow, margins widen; shares rally
F&P Healthcare 1H profit rises 18%, on record sales, wider margins